Emerging Concepts in Targeted Therapy for Basal Cell Carcinoma: New Frontiers for Evidence-Based Practice

I have read the CME Disclosures

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Providership of Cine-Med and the Angiogenesis Foundation. Cine-Med is accredited by the ACCME to provide continuing medical education for physicians.

Cine-Med designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.

Date of original release: April 30, 2014
Date of expiration: April 29, 2015
CME Course Code: 2014BCC

Practicing oncologists, dermatologists, and primary care physicians in the U.S., researchers and medical students

Cancer of the skin (including melanoma and basal and squamous cell skin cancers) is by far the most common of all types of cancer. An estimated 3.5 million basal and squamous cell skin cancers are diagnosed each year (occurring in about 2.2 million Americans, as some people have more than one). Most of these are basal cell cancers.

The number of these cancers has been increasing for many years. This is probably due to a combination of better skin cancer detection, people getting more sun exposure, and people living longer. The overall lifetime risk for BCCs is estimated to be approximately 30%. The risk of development increases with age reaching its peak during sixth to eighth decades.

At the completion of this activity, participants should be able to:

  • Assess new data on novel agents and combination regimens for the management of non-melanoma skin cancer
  • Describe recent clinical data evaluating signaling pathway inhibitors for the treatment of BCC
  • Apply recent, practice-changing developments in the treatment of basal cell carcinoma to the management of patients with advanced or metastatic disease
  • Manage adverse events and safety issues associated with the treatment of basal cell carcinoma
  • Identify barriers to effective care of patients with BCC and identify strategies for overcoming those barriers

This activity is designed to address the following ABMS / IOM competencies:
Patient Care and Medical Knowledge

There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Angiogenesis Foundation's website (http://www.cmeonline.org) by selecting the name of the program (registration required). Course code: 2014BCC

This activity is supported by educational grants from Genentech.

William Li, MD
Dartmouth Medical College

Cine-Med asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Cine-Med has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

William W. Li, M.D.
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.

Emerging Concepts in Targeted Therapy for Basal Cell Carcinoma:

  • Overview of Basal Cell Carcinoma
  • Mechanisms and Pathways of BCC
  • Clinical Progress in BCC for Targeted Therapy
  • Current Clinical Challenges in Targeted Therapy of BCC
  • Future Directions

This educational program is available as a mobile application and a PDF file. The mobile application can be run on any iOS or Android device. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.

For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.